Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.
Institute for Data, Systems, and Society, Massachusetts Institute of Technology, Cambridge.
JAMA Neurol. 2023 Sep 1;80(9):919-928. doi: 10.1001/jamaneurol.2023.2226.
Adults with Alzheimer disease and related dementias (ADRD) are particularly vulnerable to the direct and indirect effects of the COVID-19 pandemic. Deaths associated with ADRD increased substantially in pandemic year 1. It is unclear whether mortality associated with ADRD declined when better prevention strategies, testing, and vaccines became widely available in year 2.
To compare pandemic-era excess deaths associated with ADRD between year 1 and year 2 overall and by age, sex, race and ethnicity, and place of death.
DESIGN, SETTING, AND PARTICIPANTS: This time series analysis used all death certificates of US decedents 65 years and older with ADRD as an underlying or contributing cause of death from January 2014 through February 2022.
COVID-19 pandemic era.
Pandemic-era excess deaths associated with ADRD were defined as the difference between deaths with ADRD as an underlying or contributing cause observed from March 2020 to February 2021 (year 1) and March 2021 to February 2022 (year 2) compared with expected deaths during this period. Expected deaths were estimated using data from January 2014 to February 2020 fitted with autoregressive integrated moving average models.
Overall, 2 334 101 death certificates were analyzed. A total of 94 688 (95% prediction interval [PI], 84 192-104 890) pandemic-era excess deaths with ADRD were estimated in year 1 and 21 586 (95% PI, 10 631-32 450) in year 2. Declines in ADRD-related deaths in year 2 were substantial for every age, sex, and racial and ethnic group evaluated. Pandemic-era ADRD-related excess deaths declined among nursing home/long-term care residents (from 34 259 [95% PI, 25 819-42 677] in year 1 to -22 050 [95% PI, -30 765 to -13 273] in year 2), but excess deaths at home remained high (from 34 487 [95% PI, 32 815-36 142] in year 1 to 28 804 [95% PI, 27 067-30 571] in year 2).
This study found that large increases in mortality with ADRD as an underlying or contributing cause of death occurred in COVID-19 pandemic year 1 but were largely mitigated in pandemic year 2. The most pronounced declines were observed for deaths in nursing home/long-term care settings. Conversely, excess deaths at home and in medical facilities remained high in year 2.
患有阿尔茨海默病和相关痴呆症(ADRD)的成年人特别容易受到 COVID-19 大流行的直接和间接影响。大流行第一年与 ADRD 相关的死亡人数大幅增加。目前尚不清楚,当更好的预防策略、检测和疫苗在第二年广泛可用时,与 ADRD 相关的死亡率是否下降。
比较大流行期间与 ADRD 相关的超额死亡人数,总体上和按年龄、性别、种族和民族以及死亡地点进行比较。
设计、设置和参与者:这项时间序列分析使用了所有美国 65 岁及以上的死者的死亡证明,这些死者的 ADRD 是导致死亡的根本或促成原因,死亡时间从 2014 年 1 月至 2022 年 2 月。
COVID-19 大流行时期。
ADRD 相关的大流行期间超额死亡人数被定义为 2020 年 3 月至 2021 年 2 月(第 1 年)与 2021 年 3 月至 2022 年 2 月(第 2 年)期间观察到的 ADRD 作为根本或促成原因的死亡人数与同期预期死亡人数之间的差异。预期死亡人数是使用 2014 年 1 月至 2020 年 2 月的数据估计的,这些数据采用自回归综合移动平均模型进行拟合。
总共分析了 2334101 份死亡证明。第 1 年估计有 94688 例(95%预测区间[PI],84192-104890)与 ADRD 相关的大流行期间超额死亡人数,第 2 年有 21586 例(95%PI,10631-32450)。在评估的每个年龄、性别和种族群体中,与 ADRD 相关的死亡人数都有大幅下降。疗养院/长期护理居民的与 ADRD 相关的大流行期间超额死亡人数(从第 1 年的 34259 例[95%PI,25819-42677]降至第 2 年的-22050 例[95%PI,-30765-13273])有所下降,但在家中死亡的人数仍然很高(从第 1 年的 34487 例[95%PI,32815-36142]降至第 2 年的 28804 例[95%PI,27067-30571])。
本研究发现,与 ADRD 作为根本或促成原因的死亡人数在 COVID-19 大流行的第 1 年大幅增加,但在第 2 年已大大缓解。在疗养院/长期护理环境中死亡人数的降幅最为明显。相反,第 2 年在家中和医疗机构的超额死亡人数仍然很高。